Analyzing medical and outpatient pharmacy claims, the researchers found that semaglutide use was associated with a 49% lower adjusted hazard of COVID-19-associated mortality, especially relevant since obesity or overweight and type 2 diabetes, the primary conditions for which semaglutide may be prescribed, have consistently been associated with an increased mortality risk
doi:10.37549/ARO-D-25-00007.
Individuals with a personal family history of thyroid cancer, kidney disease, or those who have had allergic reactions to the drug should avoid it
Funding D.A.G is currently supported by grants from the NIH (R01DK094004, R01CA196986, and R01DK116005) and by a Leukemia and Lymphoma Society Career Development Award
Why GLP-1 Pens Use mg Instead of Units GLP-1 receptor agonists such as semaglutide, liraglutide, and tirzepatide are modern peptide drugs produced using precise biochemical manufacturing processes